Table 2.
Selected Ongoing Clinical Trials of Systemic Therapy for Breast Cancer Brain Metastases
| Agent | Phase of Trial | Class or Target | Patient Population | ClinicalTrials.gov Identifier |
|---|---|---|---|---|
| 2B3–101 | I | Anthracycline | Solid tumors and malignant glioma | NCT01386580 |
| TPI-287 | II | Taxane | Breast cancer, all subtypes | NCT01480583 |
| Everolimus + trastuzumab + vinorelbine | II | mTOR | Breast cancer, HER2-positive | NCT01305941 |
| BKM120 + trastuzumab | I | PI3K | Breast cancer, HER2-positive | NCT01132664 |
| Lapatinib + WBRT | II | HER2 | Breast cancer, HER2-positive | NCT01622868 |
| Neratinib | II | HER2 | Breast cancer, HER2-positive | NCT01494662 |
| Afatinib | II | HER2 | Breast cancer, HER2-positive | NCT01441596 |
| ARRY-380 + trastuzumab | I | HER2 | Breast cancer, HER2-positive | Not yet assigned |
| Bevacizumab + carboplatin | II | VEGF | Breast cancer, all subtypes | NCT01004172 |
| Bevacizumab + cisplatin + etoposide | II | VEGF | Breast cancer, all subtypes | NCT01281696 |